Universal Registration Document Including The Annual Financial Report

Overview

The report describes the company's final positive Atalante 1 Phase 3 results for Tedopi in non-small-cell lung cancer after checkpoint-inhibitor failure. It also highlights the worldwide Veloxis licensing agreement for FR104 in transplantation and continued Phase 2 development of OSE-127/S95011. CoVepiT generated positive six-month memory T-response results, although further clinical development was difficult under the circumstances.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2021
Period: Ends 31 December 2021
Publication date: 15 April 2022
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services